Patents Assigned to Merck
  • Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor
    Patent number: 6469142
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human NMDA receptor protein subunits and the proteins encoded thereby. The NMDA receptor subunits of the invention comprise components of NMDA receptors that have cation-selective channels and bind glutamate and NMDA. In one aspect of the invention, the nucleic acids encode NMDAR1 and NMDAR2 subunits of human NMDA receptors. In a preferred embodiment, the invention nucleic acids encode NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C and NMDAR2D subunits of human NMDA receptors. In addition to being useful for the production of NMDA receptor subunit proteins, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: October 22, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Lorrie P. Daggett, Chin-Chun Lu
  • Process for the scaleable purification of plasmid DNA
    Publication number: 20020151048
    Abstract: The present invention relates to a nonchromatographic-based process for the isolation of clinical grade plasmid DNA from bacterial cells. The exemplified methods described herein outline a scaleable, economically favorable protocol for the purification of clinical grade plasmid DNA from E. coli which includes CTAB-based precipitation of DNA in combination with adsorption of impurities to calcium silicate.
    Type: Application
    Filed: April 1, 2002
    Publication date: October 17, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Russel Jackson Lander, Michael Albert Winters, Francis Jeremiah Meacle
  • Pigment preparation for anticorrosion paints
    Publication number: 20020148390
    Abstract: The invention relates to pigment preparations for anticorrosion paints which are employed in primers for metallic objects, have a good corrosion-protection action and consist of from 1 to 99% by weight of one or more compounds which absorb OH− ions and from 1 to 99% by weight of one or more compounds which catalyze an oxygen-reduction reaction on a metallic substrate.
    Type: Application
    Filed: February 13, 2002
    Publication date: October 17, 2002
    Applicant: Merck Patent GmbH
    Inventor: Ralf Glausch
  • Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase
    Publication number: 20020151459
    Abstract: The present invention relates to methods for identifying compounds useful as inhibitors of farnesyl diphosphate synthase. More particularly, the compounds so identified are useful for inhibiting bone resorption. The present invention also relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a farnesyl diphosphate synthase inhibitor.
    Type: Application
    Filed: April 11, 2002
    Publication date: October 17, 2002
    Applicant: Merck & Co., Inc.
    Inventors: James D. Bergstrom, Alfred A. Reszka, Gideon A. Rodan
  • Pyrones as inhibitors of cyclooxygenase-2
    Patent number: 6465509
    Abstract: The invention encompasses the novel compounds of Formula I, which are useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cyclooxygenase-2 mediated diseases comprising administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Formula I.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun-Sing Li, Cheuk Kun Lau, Michel Therien, Petpiboon Prasit
  • Method for removing initiators from grafting products
    Patent number: 6465600
    Abstract: The present invention relates to a process for removing an initiator of cerium (IV) salt from a graft product. The process may include washing the graft product with a mineral acid solution comprising ascorbic acid.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck Patent Geselleschaft mit beschranhkter Haftung
    Inventors: Lothar Britsch, Egbert Müller, Josef-Stefan Stöhr
  • Method of preparing a broadband reflective polarizer
    Patent number: 6466297
    Abstract: The invention relates to a method of preparing a broadband reflective polarizer comprising the blending a first mixture A comprising at least one achiral polymerizable mesogenic compound with a second mixture B comprising at least one chiral polymerizable mesogenic compound; and coating a layer of the blended mixture onto a first substrate and aligning the chiral mesogenic material in a planar orientation so that the axis of the molecular helix extends transversely to the layer.
    Type: Grant
    Filed: July 3, 2000
    Date of Patent: October 15, 2002
    Assignee: Merck Patent Geselleschaft mit Beschrankter Haftung
    Inventors: Mark Goulding, David Coates, John Patrick, Mark Verrall, John Argent
  • Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
    Patent number: 6465444
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: October 15, 2002
    Assignees: Merck Frosst Canada & Co., Banyu Pharmaceutical Co., Ltd.
    Inventors: Christopher Bayly, Mitsuru Ohkubo
  • Liquid-crystalline medium
    Patent number: 6465059
    Abstract: The invention relates to a liquid-crystalline medium one or more compounds of the general formula IA and one or more compounds of the formula IB R, R*, R**, z, L and Y are defined herein.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: October 15, 2002
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Matthias Bremer, Georg Lüssem, Dagmar Klement
  • Method for inhibiting bone resorption
    Patent number: 6465443
    Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
  • Substituted triazolo pyridazine derivatives as inverse agonists of the GABAA&agr;5 receptor subtype
    Patent number: 6465462
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof are useful in enhancing cognition.
    Type: Grant
    Filed: January 14, 1999
    Date of Patent: October 15, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: William Robert Carling, Angus Murray MacLeod, Ruth McKernan, Austin John Reeve, Francine Sternfeld, Leslie Joseph Street
  • Arylthiazolidinedione derivatives
    Patent number: 6465497
    Abstract: Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr; and/or &ggr; mediated diseases, disorders and conditions.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ranjit C. Desai, Soumya P. Sahoo, Jeffrey P. Bergman, Victoria K. Lombardo, Edward J. Metzger, Hiroo Koyama
  • Angiogenesis inhibitors
    Patent number: 6465484
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tryrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Randall W. Hungate, April M. Cunningham, Timothy J. Koester
  • Tyrosine kinase inhibitors
    Publication number: 20020147203
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 1, 2002
    Publication date: October 10, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
  • Polynucleotide herpes virus vaccine
    Publication number: 20020147167
    Abstract: Genes encoding herpes simplex virus type 2 (HSV-2) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. In a DNA titration, it was found that a single immunization of ≧0.5 &mgr;g of (one) PNV, gave >90% seroconversion by ten weeks post immunization. Immune antisera neutralized both HSV-2 and HSV-1 in cell culture. When animals were challenged with HSV-2, significant (p<0.001) protection from lethal infection was achieved following PNV vaccination. DNA constructs may be full-length, truncated and/or mutated forms and may be delivered along or in combination in order to optimize immunization and protection from HSV infection.
    Type: Application
    Filed: April 16, 2001
    Publication date: October 10, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Marcy E. Armstrong, Robert D. Keys, John A. Lewis, Margaret A. Liu, William L. McClements
  • Thrombin inhibitors
    Patent number: 6462050
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure:
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: October 8, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Richard C. Isaacs, Kellie Cutrona, James C. Barrow, Harold G. Selnick
  • Cannula operated pinch valve
    Patent number: 6461345
    Abstract: There is disclosed a pinch valve for allowing access to a sterile reaction vessel using a cannula. The valve remains closed until a cannula is inserted. Upon removal of the cannula, the valve automatically closes maintaining the sterile or otherwise controlled conditions of the reaction vessel.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: October 8, 2002
    Assignee: Merck & Co., Inc.
    Inventor: Gary S. Kath
  • Oxazolidines as 5-HT2A-antagonists
    Patent number: 6462056
    Abstract: The invention relates to novel oxazolidine derivatives of the formula in which R1, R2 and R3 have the meanings stated in claim 1, their salts and processes for preparing the compounds according to the invention. The compounds of the formula I act as 5-HT2A antagonists with a 5-HT reuptake-inhibiting, antidepressant or anxiolytic effect and can be used to produce pharmaceuticals.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: October 8, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Henning Böttcher, Helmut Prücher, Hartmut Greiner, Gerd Bartoszyk, Christoph Seyfried
  • Method for treating premenstrual or late luteal phase syndrome
    Publication number: 20020142942
    Abstract: A tachykinin receptor antagonist is useful for alleviating or managing symptoms associated with premenstrual syndrome in a woman, in particular, for the treatment or prevention of disturbances of appetite, disturbances of mood, or both, associated with premenstrual syndrome.
    Type: Application
    Filed: March 25, 2002
    Publication date: October 3, 2002
    Applicant: Merck & Co. Inc.
    Inventors: Bennett M. Shapiro, Nadia Rupniak
  • Micromixer
    Patent number: 6457854
    Abstract: The inventive micromixer for mixing liquid, viscous or gaseous phases has a housing bottom part (2) and a housing top part (3) which lie closely against each other via connecting surfaces (6, 7). Two delivery channels (1a, 1b) and an outlet channel (5) open out into the dividing surface between the two connecting surface (6, 7). Channel grooves (9, 10) which cross each other several times are formed in one connecting surfaces (6) and provide a mixing section for the phases being mixed.
    Type: Grant
    Filed: April 24, 2000
    Date of Patent: October 1, 2002
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Ulrich Koop, Michael Schmelz, Andreas Beirau